2024
The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas
Kinslow C, Roy S, Iwamoto F, Brown P, DeStephano D, Canoll P, Qureshi S, Gallito M, Sisti M, Bruce J, Horowitz D, Kachnic L, Neugut A, Yu J, Mehta M, Cheng S, Wang T. The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas. Neuro-Oncology 2024, 26: 1839-1849. PMID: 38943513, PMCID: PMC11449043, DOI: 10.1093/neuonc/noae102.Peer-Reviewed Original ResearchProgression-free survivalIDH-mutant gliomasLow grade gliomasOverall survivalIDH-wtAlkylating chemotherapyGrade gliomasChemotherapy improves overall survivalMeta-analysis of randomized clinical trialsEffects of alkylating chemotherapyCompared to radiotherapyIDH-mutant tumorsWorld Health OrganizationIDH-wt glioblastomaIDH-wt gliomasMeta-analysisDiagnosis of glioblastomaIDH-wt tumorsIDH-wild typeRandomized clinical trialsRandom-effects modelMagnitude of benefitGlioblastoma trialsAnaplastic morphologyOS benefit
2021
Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer
Rodrigues Pessoa R, Mueller A, Boxley P, Flaig T, Piper C, Konety B, Yu J, Gershman B, Kukreja J, Kim S. Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer. Urologic Oncology Seminars And Original Investigations 2021, 39: 786.e1-786.e8. PMID: 33846085, DOI: 10.1016/j.urolonc.2021.03.009.Peer-Reviewed Original ResearchConceptsHigh-risk non-muscle invasive bladder cancerNon-muscle invasive bladder cancerCancer specific-survivalRecurrence-free survivalInvasive bladder cancerBacillus Calmette-GuerinOverall survivalRadiation therapyBladder cancerMeta-analysisRates of recurrence-free survivalClinical trialsGoal of bladder preservationMetastatic disease rateSalvage radical cystectomyCochrane Central Register of Controlled TrialsProspective clinical trialCentral Register of Controlled TrialsTreatment of patientsRegister of Controlled TrialsSystematic reviewCochrane Central RegisterLow-quality evidenceQuality of evidenceBladder preservation
2020
Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials
Lehrer E, Kishan A, Yu J, Trifiletti D, Showalter T, Ellis R, Zaorsky N. Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials. Radiotherapy And Oncology 2020, 148: 235-242. PMID: 32505965, DOI: 10.1016/j.radonc.2020.04.037.Peer-Reviewed Original ResearchConceptsConventionally fractionated radiation therapyHypofractionated radiation therapyUltrahypofractionated radiation therapyLate grade 2Radiation therapyGrade 2Weighted random effects meta-analysesSummary effect sizesLocalized prostate cancerCompare treatment modalitiesDerSimonian and Laird methodPhase III protocolsRandom-effects meta-analysesGenitourinary toxicityEffects meta-analysesGastrointestinal toxicityProspective trialsMedian ageProstate cancerTreatment modalitiesComparing patientsIII protocolLaird methodTherapyMeta-analysis
2019
Stereotactic Body Radiation Therapy Vs Hypofractionated Intensity Modulated Radiation Therapy for Localized Prostate Cancer (SHRAPNEL): An International Meta-Analysis of 24 Prospective Trials
Lehrer E, Kishan A, Yu J, Trifiletti D, Showalter T, Ellis R, Zaorsky N. Stereotactic Body Radiation Therapy Vs Hypofractionated Intensity Modulated Radiation Therapy for Localized Prostate Cancer (SHRAPNEL): An International Meta-Analysis of 24 Prospective Trials. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e289. DOI: 10.1016/j.ijrobp.2019.06.1829.Peer-Reviewed Original Research